Business Context and Reporting Period
This Form 8-K is filed by ReShape Lifesciences Inc. (RSLS) on May 28, 2025. The filing relates to the previously announced Merger Agreement dated July 8, 2024, between ReShape and Vyome Therapeutics, Inc. (Vyome). The report serves to incorporate Vyome's financial statements and management discussion for the quarter ended March 31, 2025, and the year ended December 31, 2024, into ReShape's shelf registration statement (Form S-3). The merger is subject to conditions, including Nasdaq approval for the combined company.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached exhibits (Exhibits 99.1 through 99.5) which are incorporated by reference but not detailed in the body of this 8-K summary.
Material Changes
No material changes in financial performance are detailed in the text of this filing. The primary event is the procedural update regarding the pending merger and the submission of Vyome's historical financial data to support the transaction.
Guidance, Outlook, and Risks
- Merger Status: The transaction remains subject to the satisfaction or waiver of conditions, specifically including Nasdaq's approval of a new listing application for the combined entity.
- Regulatory Filing: The financial data is being filed to satisfy requirements for ReShape's Form S-3 shelf registration statement.
- Outlook: No specific forward-looking guidance or management commentary on future operations is included in the text of this report.
Investor Verification Checklist
- Verify the specific financial figures for Vyome in Exhibit 99.1 (Q1 2025 Financial Statements) and Exhibit 99.3 (2024 MD&A).
- Review the Unaudited Pro Forma Condensed Combined Financial Statements in Exhibit 99.5 to understand the projected financial position of the combined company.
- Confirm the status of Nasdaq's listing approval for the post-merger entity, as this is a stated condition precedent.
- Check the Form S-3 (File No. 333-287168) to see how the incorporated data impacts ReShape's capital raising capabilities.